Press Releases
Biopure Corporation
(ticker: BPUR, exchange: NASDAQ)
Biopure Corporation Raises $17 Million Through Sale Of Common Stock
Cambridge, MA - July 23, 2003 — PRNewswire-FirstCall — Biopure Corporation (Nasdaq: BPUR) today announced that it has raised $17.2 million in gross proceeds through the sale of 3,083,000 shares of its common stock at $5.58 per share. The company intends to use the estimated net proceeds of approximately $16.2 million for general corporate purposes, including capital expenditures and to meet working capital needs. ThinkEquity LLC, acted as the placement agent for the offering.
Biopure sold all of these shares to a group of investors under a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission. Copies of the prospectus and prospectus supplements for the issuance of Biopure's common stock can be obtained in the company's filings with the U.S. Securities and Exchange Commission (SEC), which can be accessed in the EDGAR database at the SEC website at www.sec.gov, or via written request to ThinkEquity LLC, 28 W. 44th Street, Suite 1200, New York, NY 10036.
Biopure Corporation, headquartered in Cambridge, Mass., is the leading manufacturer and marketer of oxygen therapeutics, a new class of drugs that are intravenously administered to deliver oxygen to the body's tissues for the treatment of acutely anemic surgical patients and other potential medical applications.
Contact:
Douglas Sayles
Biopure Corporation
(617) 234-6826
PR@biopure.com
Lee Stern (investors)
The Trout Group
(212) 477-9007 x22
lstern@troutgroup.com
SOURCE Biopure Corporation
07/23/2003
Web site: http://www.biopure.com/
© 2003 Biopure Corporation